Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Theratechnologies Inc
Bullboard Posts
User Avatar Image
(3)
•••
Comment by longterm56on Dec 07, 2018 9:45am
101 Views
Post# 29081476

RE:RE:Big Picture

RE:RE:Big Picture
palinc2000 wrote:
longterm56 wrote: Although I can get quite cynical at times ... especially with SPCEO1's longterm, blatant, and continuous optimism ...  I have to say that there is MUCH more upside potential than downside risk with THERF. With Trogarzo, it has cleared all the risky boxes and the only thing left is "how will it sell?" (good/better/best).  With Egrifta ... solid performer with a few opportunities to really excel!

I'm embarassed to mention the total exposure I have with THERF, but ... for me ... right now ... long and strong!  

  -LT
 
What do you consider GOOD in your good better best scenario forTrogarzo?



Since I got in at a pretty low price, "good" (for me) is anything above C $8 ... in other words, it's already good.

  -LT
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities